BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30975125)

  • 1. Functional role of SGK3 in PI3K/Pten driven liver tumor development.
    Cao H; Xu Z; Wang J; Cigliano A; Pilo MG; Ribback S; Zhang S; Qiao Y; Che L; Pascale RM; Calvisi DF; Chen X
    BMC Cancer; 2019 Apr; 19(1):343. PubMed ID: 30975125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
    Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
    Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.
    Wang C; Che L; Hu J; Zhang S; Jiang L; Latte G; Demartis MI; Tao J; Gui B; Pilo MG; Ribback S; Dombrowski F; Evert M; Calvisi DF; Chen X
    Liver Int; 2016 Aug; 36(8):1176-86. PubMed ID: 26716908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues.
    Scheiter A; Evert K; Reibenspies L; Cigliano A; Annweiler K; Müller K; Pöhmerer LM; Xu H; Cui G; Itzel T; Materna-Reichelt S; Coluccio A; Honarnejad K; Teufel A; Brochhausen C; Dombrowski F; Chen X; Evert M; Calvisi DF; Utpatel K
    Mol Oncol; 2022 Mar; 16(5):1091-1118. PubMed ID: 34748271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/β-catenin signaling pathways.
    Kong X; Liu F; Gao J
    Oncotarget; 2016 Oct; 7(40):66051-66060. PubMed ID: 27602769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.
    Xu Z; Hu J; Cao H; Pilo MG; Cigliano A; Shao Z; Xu M; Ribback S; Dombrowski F; Calvisi DF; Chen X
    Exp Mol Med; 2018 Jan; 50(1):e417. PubMed ID: 29303510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3β/β-catenin signalling.
    Liu F; Wu X; Jiang X; Qian Y; Gao J
    J Exp Clin Cancer Res; 2018 Jun; 37(1):122. PubMed ID: 29940988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma.
    Liu M; Chen L; Chan TH; Wang J; Li Y; Li Y; Zeng TT; Yuan YF; Guan XY
    Hepatology; 2012 Jun; 55(6):1754-65. PubMed ID: 22262416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
    Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
    Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
    Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
    Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
    Ghodsinia AA; Lego JMT; Garcia RL
    Cells; 2020 Apr; 9(5):. PubMed ID: 32365913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
    Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS
    J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
    Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
    Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
    Vasudevan KM; Barbie DA; Davies MA; Rabinovsky R; McNear CJ; Kim JJ; Hennessy BT; Tseng H; Pochanard P; Kim SY; Dunn IF; Schinzel AC; Sandy P; Hoersch S; Sheng Q; Gupta PB; Boehm JS; Reiling JH; Silver S; Lu Y; Stemke-Hale K; Dutta B; Joy C; Sahin AA; Gonzalez-Angulo AM; Lluch A; Rameh LE; Jacks T; Root DE; Lander ES; Mills GB; Hahn WC; Sellers WR; Garraway LA
    Cancer Cell; 2009 Jul; 16(1):21-32. PubMed ID: 19573809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma.
    Chen D; Li Z; Cheng Q; Wang Y; Qian L; Gao J; Zhu JY
    J Clin Pathol; 2019 Sep; 72(9):588-596. PubMed ID: 31126975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.